- $19.14m
- $6.51m
- $28.94m
- 24
- 59
- 20
- 26
Annual balance sheet for BioLine RX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 22.6 | 57.1 | 51.1 | 43 | 19.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.141 | 0.142 | 0.721 | 1.19 | 3.95 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 22.9 | 57.4 | 52 | 47.2 | 27.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.7 | 2.28 | 2.5 | 1.89 | 1.35 |
| Net Intangible Assets | |||||
| Total Assets | 47.3 | 81.4 | 76.4 | 63.9 | 38.9 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.6 | 9.72 | 10.7 | 30.9 | 15.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25.3 | 13.3 | 25.5 | 50.7 | 25.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 22 | 68.1 | 50.8 | 13.2 | 13.5 |
| Total Liabilities & Shareholders' Equity | 47.3 | 81.4 | 76.4 | 63.9 | 38.9 |
| Total Common Shares Outstanding |